Patent Assignment
Reel/Frame 062937/0311
Release of Security Interest
Recorded: 2023-03-09
Pages: 13
Assignor
PONTIFAX MEDISON FINANCE GP, L.P.
Executed: 2023-03-02
Assignee
OPIANT PHARMACEUTICALS, INC.
10710 MIDLOTHIAN TURNPIKE, SUITE 125, NORTH CHESTERFIELD, VIRGINIA, 23235
Covered Properties
(33)
Compositions, Devices, and Methods for the Treatment of Alcohol Use Disorder
PCT:
PCT/US2017/039300 ↗
Compositions, Devices, and Methods for the Treatment of Opioid-Receptor-Mediated Conditions
PCT:
PCT/US2017/060963 ↗
Compositions and Methods for the Treatment of Opioid Overdose
PCT:
PCT/US2017/060964 ↗
Formulations and Methods for the Prevention of Opioid Overdose
PCT:
PCT/US2019/032498 ↗
Methods, Parenteral Pharmaceutical Formulations, and Devices for the Prevention of Opioid Overdose
PCT:
PCT/US2019/060185 ↗
Compositions and Methods for Treating Acute Cannabinoid Overdose with a Cannabinoid Receptor Antagonist
PCT:
PCT/US2019/064672 ↗
Compositions, Devices, and Methods for the Treatment of Overdose and Reward-Based Disorders
PCT:
PCT/US2019/067513 ↗
Compositions and Methods for Treating Acute Cannabinoid Overdose with a Cannabinoid Receptor Antagonist
PCT:
PCT/US2020/038211 ↗
Compositions and Methods for Treating Cannabinoid Hyperemesis Syndrome with a Cannabinoid Receptor Antagonist
PCT:
PCT/US2020/038215 ↗
Pharmaceutical Compositions Containing Azetidine Derivatives, Novel Azetidine Derivatives and Their Preparation
Patent:
6,355,631 →
Application:
09/798,452 →
Method and Intermediates for the Preparation of Derivatives of N (1-Benzhydrylazetidin-3-Yl)-N-Phenylmethylsulfonamide
Method and Intermediates for the Preparation of Derivatives of N (1-Benzhydrylazetidin-3-Yl)-N-Phenylmethylsulfonamide
Method for Preparing Azetidine Derivatives
Compositions for Oral Drug Administration
Application:
13/951,284 →
Publication:
US 2014/0162965
Compositions for Drug Administration
Induction of Highly Specific Antibodies to a Hapten but Not to a Carrier Peptide by Immunization
Anti-Bacterial Compositions for Drug Administration
Application:
15/465,406 →
Publication:
US 2017/0189472
Compositions and Methods for Treating Acute Cannabinoid Overdose with a Cannabinoid Receptor Antagonist
Application:
16/704,699 →
Publication:
US 2020/0179271
Compositions, Devices, and Methods for the Treatment of Overdose and Reward-Based Disorders
Application:
16/721,872 →
Publication:
US 2020/0390691
Compositions and Methods for Treating Cannabinoid Hyperemesis Syndrome with a Cannabinoid Receptor Antagonist
Compositions and Methods for Treating Acute Cannabinoid Overdose with a Cannabinoid Receptor Antagonist
Application:
16/904,403 →
Publication:
US 2020/0397749
Compositions and Methods for the Treatment of Alcohol Use Disorder
Application:
62/354,465 →
Compositions and Methods for the Treatment of Alcohol Ususe Disorder
Application:
62/419,736 →
Compositions and Methods for the Treatment of Opioid Overdose and Opioid Receptor Mediated Conditions
Application:
62/419,743 →
Compositions and Methods for the Treatment of Opioid Overdose
Application:
62/424,378 →
Compositions, Devices, and Methods for the Treatment of Opioid-Overdose and Opioid-Receptor-Mediated Conditions
Application:
62/525,057 →
Formulations and Methods for the Prevention of Opioid Overdose
Application:
62/672,950 →
Methods, Parenteral Pharmaceutical Formulations, and Devices for the Prevention of Opioid Overdose
Application:
62/756,903 →
Compositions and Methods for Treating Acute Cannabinoid Overdose with a Cannabinoid Receptor Antagonist
Application:
62/776,888 →
Compositions, Devices, and Methods for the Treatment of Overdose and Reward-Based Disorders
Application:
62/782,943 →
Compositions and Methods for Treating Cannabinoid Hyperemesis Syndrome with a Cannabinoid Receptor Antagonist
Application:
62/862,830 →
Compositions and Methods for Treating Acute Cannabinoid Overdose with a Cannabinoid Receptor Antagonist
Application:
62/862,832 →
Compositions and Methods for Treating Acute Cannabinoid Overdose with a Cannabinoid Receptor Antagonist
Application:
63/037,351 →
Related Assignments
(25)
Other recorded transfers of the patents in this record — the chain of ownership.
Change of Name
Jun 20, 2012
From: SANOFI-AVENTIS
To: SANOFI
Reel/Frame 028413/0927 →
Assignment of Assignor's Interest
May 20, 2014
From: MAGGIO, EDWARD T
To: AEGIS THERAPEUTICS , LLC
Reel/Frame 032935/0044 →
Assignment of Assignor's Interest
Sep 24, 2015
From: ALVING, CARL; MATYAS, GARY
To: THE GOVERNMENT OF THE UNITED STATES AS REPRESENTED BY THE SECRETARY OF THE ARMY
Reel/Frame 036680/0119 →
Assignment of Assignor's Interest
Oct 20, 2015
From: ALVING, CARL; MATYAS, GARY R
To: UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE ARMY
Reel/Frame 036907/0815 →
Assignment of Assignor's Interest
Nov 28, 2016
From: CRYSTAL, ROGER
To: OPIANT PHARMACEUTICALS, INC.
Reel/Frame 040691/0896 →
Assignment of Assignor's Interest
Nov 28, 2016
From: CRYSTAL, ROGER; AGRAWAL, ARVIND
To: OPIANT PHARMACEUTICALS, INC.
Reel/Frame 040725/0534 →
Assignment of Assignor's Interest
Dec 21, 2016
From: AGRAWAL, ARVIND
To: OPIANT PHARMACEUTICALS, INC.
Reel/Frame 041157/0931 →
Assignment of Assignor's Interest
Apr 21, 2017
From: MAGGIO, EDWARD T.
To: AEGIS THERAPEUTICS, LLC
Reel/Frame 042118/0390 →
Assignment of Assignor's Interest
Nov 6, 2017
From: CRYSTAL, ROGER
To: OPIANT PHARMACEUTICALS, INC.
Reel/Frame 044043/0239 →
Assignment of Assignor's Interest
Nov 6, 2017
From: CRYSTAL, ROGER
To: OPIANT PHARMACEUTICALS, INC.
Reel/Frame 044043/0118 →
Assignment of Assignor's Interest
Nov 6, 2017
From: CRYSTAL, ROGER
To: OPIANT PHARMACEUTICALS, INC.
Reel/Frame 044043/0302 →
Assignment of Assignor's Interest
Jan 16, 2019
From: AVENTIS PHARMA S.A.
To: SANOFI MATURE IP
Reel/Frame 048031/0046 →
Assignment of Assignor's Interest
Aug 20, 2019
From: SKOLNICK, PHIL
To: OPIANT PHARMACEUTICALS, INC.
Reel/Frame 050109/0878 →
Assignment of Assignor's Interest
Aug 20, 2019
From: SKOLNICK, PHIL
To: OPIANT PHARMACEUTICALS, INC.
Reel/Frame 050105/0361 →
Assignment of Assignor's Interest
Oct 21, 2019
From: SKOLNICK, PHIL
To: OPIANT PHARMACEUTICALS, INC.
Reel/Frame 050782/0266 →
Assignment of Assignor's Interest
Oct 21, 2019
From: CRYSTAL, ROGER; SKOLNICK, PHIL
To: OPIANT PHARMACEUTICALS, INC.
Reel/Frame 050782/0228 →
Assignment of Assignor's Interest
Oct 28, 2019
From: CRYSTAL, ROGER; ELLISON, MARK
To: OPIANT PHARMACEUTICALS, INC.
Reel/Frame 050846/0389 →
Assignment of Assignor's Interest
Dec 2, 2019
From: MAGGIO, EDWARD T.
To: AEGIS THERAPEUTICS, LLC
Reel/Frame 051154/0502 →
Assignment of Assignor's Interest
Aug 6, 2020
From: MAGGIO, EDWARD T.
To: AEGIS THERAPEUTICS, LLC
Reel/Frame 053419/0262 →
Assignment of Assignor's Interest
Aug 6, 2020
From: CRYSTAL, ROGER; ELLISON, MARK; SKOLNICK, PHIL
To: OPIANT PHARMACEUTICALS, INC.
Reel/Frame 053419/0829 →
Security Interest
Dec 10, 2020
From: OPIANT PHARMACEUTICALS, INC.
To: PONTIFAX MEDISON FINANCE GP, L.P.
Reel/Frame 054602/0192 →
Assignment of Assignor's Interest
May 6, 2021
From: CRYSTAL, ROGER; SKOLNICK, PHIL
To: OPIANT PHARMACEUTICALS, INC.
Reel/Frame 056164/0157 →
Assignment of Assignor's Interest
Jun 2, 2021
From: SKOLNICK, PHIL
To: OPIANT PHARMACEUTICALS, INC.
Reel/Frame 056410/0198 →
Security Interest
Aug 6, 2021
From: NEURELIS, INC.; AEGIS THERAPEUTICS, LLC
To: ORBIMED ROYALTY & CREDIT OPPORTUNITIES III, LP
Reel/Frame 057111/0242 →
Assignment of Assignor's Interest
Apr 19, 2022
From: AGRAWAL, ARVIND
To: OPIANT PHARMACEUTICALS, INC.
Reel/Frame 059636/0984 →